RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Armored immune cells take on tough lymphoma in early trial
Disease control Recruiting nowThis early-stage study tests a new type of CAR-T cell therapy that has been 'armored' with an anti-PD1 feature to help it fight cancer better. It is for adults with diffuse large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to see…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Phase: PHASE1 • Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New combo aims to boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether adding two drugs—chidamide and a PD-1 inhibitor—after CAR-T cell therapy can help people with relapsed or hard-to-treat B-cell lymphoma stay cancer-free longer. About 30 adults with aggressive lymphoma that has come back or not responded to treatment will…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 13, 2026 16:03 UTC